GSK receives marketing authorisation from the European Commission for additional Revolade™ (eltrombopag) indication as the first approved treatment for chronic hepatitis C-associated thrombocytopenia
GlaxoSmithKline plc announced today that the European Commission has
granted an additional indication for Revolade™ (eltrombopag) as a
treatment for low platelet counts (thrombocytopenia) in adult patients
with chronic hepatitis C infection, where the degree of thrombocytopenia
is the main factor preventing the initiation or limiting the ability to
maintain optimal interferon (IFN)-based therapy.
Thrombocytopenia (platelet count ≤150Gi/L) can occur in people with
chronic hepatitis C infection as a consequence of liver damage. It is also a common side effect of peginterferon (pIFN)-based therapy.